Antimicrobial Resistance in Stenotrophomonas maltophilia: Mechanisms and Clinical Implications

Li, Xian-Zhi; Li, Jennifer

doi:10.1007/978-3-319-47266-9_11

Cited by 8 publications

(5 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like A. baumannii, it possesses a relatively impermeable membrane, and like P. aeruginosa, it expresses efflux pumps and acquires additional resistance determinants in class 1 integrons. Key mechanisms of resistance include the production of inducible ß-lactamases, and aminoglycosides-modifying enzymes, listed in Table 1 [45,51,52]. The S. maltophilia chromosome harbors two ß-lactamases: L1, an MBL with carbapenemase activity that does not hydrolyze aztreonam, and L2, a serine cephalosporinase that can be inhibited by clavulanic acid [51,53].…”

Section: Clinical Impact and Mechanisms Of Resistancementioning

confidence: 99%

Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy

Chakhtoura

Saade

Iovleva

et al. 2018

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Non-fermenting Gram-negative bacilli are at the center of the antimicrobial resistance epidemic. Acinetobacter baumannii and Pseudomonas aeruginosa are both designated with a threat level to human health of 'serious' by the Centers for Disease Control and Prevention. Two other major non-fermenting Gram-negative bacilli, Stenotrophomonas maltophilia and Burkholderia cepacia complex, while not as prevalent, have devastating effects on vulnerable populations, such as those with cystic fibrosis, as well as immunosuppressed or hospitalized patients. Areas covered: In this review, we summarize the clinical impact, presentations, and mechanisms of resistance of these four major groups of non-fermenting Gram-negative bacilli. We also describe available and promising novel therapeutic options and strategies, particularly combination antibiotic strategies, with a focus on multidrug resistant variants. Expert commentary: We finally advocate for a therapeutic approach that incorporates in vitro antibiotic susceptibility testing with molecular and genotypic characterization of mechanisms of resistance, as well as pharmacokinetics and pharmacodynamics (PK/PD) parameters. The goal is to begin to formulate a precision medicine approach to antimicrobial therapy: a clinical-decision making model that integrates bacterial phenotype, genotype and patient's PK/PD to arrive at rationally-optimized combination antibiotic chemotherapy regimens tailored to individual clinical scenarios.

show abstract

Section: Clinical Impact and Mechanisms Of Resistancementioning

confidence: 99%

Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy

Chakhtoura

Saade

Iovleva

et al. 2018

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…Despite A. baumannii, B. metallica, E. coli, K. pneumoniae, P. aeruginosa, S. Enteritidis and S. Typhimurium being resistant to the fractions in the tested concentrations, S. maltophilia strains showed high sensitivity to them, with a MIC value of 12.5 µg/mL for the 80% fraction and 25 µg/mL for the 100% towards strains 700475 and 13636, while strain 13637 showed higher sensitivity, with a MIC value of 12.5 µg/mL for both fractions. This is a very promising finding, as S. maltophilia possesses high level of intrinsic resistance to many antimicrobials and it is also readily able to acquire multidrug resistance when exposed to different antibiotics [53,54].…”

Section: Antimicrobial Activitymentioning

confidence: 99%

Characterization of a New Mixture of Mono-Rhamnolipids Produced by Pseudomonas gessardii Isolated from Edmonson Point (Antarctica)

et al. 2020

View full text Add to dashboard Cite

Rhamnolipids (RLs) are surface-active molecules mainly produced by Pseudomonas spp. Antarctica is one of the less explored places on Earth and bioprospecting for novel RL producer strains represents a promising strategy for the discovery of novel structures. In the present study, 34 cultivable bacteria isolated from Edmonson Point Lake, Ross Sea, Antarctica were subjected to preliminary screening for the biosurfactant activity. The positive strains were identified by 16S rRNA gene sequencing and the produced RLs were characterized by liquid chromatography coupled to high resolution mass spectrometry (LC-HRESIMS) and liquid chromatography coupled with tandem spectrometry (LC-MS/MS), resulting in a new mixture of 17 different RL congeners, with six previously undescribed RLs. We explored the influence of the carbon source on the RL composition using 12 different raw materials, such as monosaccharides, polysaccharides and petroleum industry derivatives, reporting for the first time the production of RLs using, as sole carbon source, anthracene and benzene. Moreover, we investigated the antimicrobial potential of the RL mixture, towards a panel of both Gram-positive and Gram-negative pathogens, reporting very interesting results towards Listeria monocytogenes with a minimum inhibitory concentration (MIC) value of 3.13 µg/mL. Finally, we report for the first time the antimicrobial activity of RLs towards three strains of the emerging multidrug resistant Stenotrophomonas maltophilia with MIC values of 12.5 µg/mL.

show abstract

“…A study by Lee et al [15] demonstrated that antibiotic resistance is formed quite rapidly in case of infection caused by gram-negative microorganisms. For instance, Stenotrophomonas maltophilia, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae strains that appear in many studies are nosocomial infection strains (pneumonia, catheter sepsis); they enter the patient's body before treatment with carbopenem, resulting in the production of βlactamases [29][30][31].…”

Section: Meropenemmentioning

confidence: 99%

Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods

Berlina¹,

Zherdev²,

Dzantiev³

2019

Preprint

View full text Add to dashboard Cite

In the modern world, the problem of antibiotic therapy is acute. Despite the diversity of existing antibiotic drugs, their efficacy decreases as new, resistant forms of pathogenic microorganisms emerge. It is extremely difficult to control such processes and even more difficult to treat severe bacterial infections. In such situations, an individual approach to each patient is required and physicians need parameters to estimate the efficacy of antibiotic therapy. This review discusses the significance of monitoring the content of antibiotics in the blood for this purpose, in combination with the content of inflammatory markers, such as C-reactive protein and procalcitonin. The basic principles of antibiotic therapy, and factors in the resistance of microorganisms to antibiotics, are examined. Approaches to assess the efficacy of antibiotic therapy, as well as methods to detect antibiotics and inflammatory markers in the blood of patients, and comparative assessment of their capabilities and limitations, are described.

show abstract

Antimicrobial Resistance in Stenotrophomonas maltophilia: Mechanisms and Clinical Implications

Cited by 8 publications

References 223 publications

Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy

Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy

Characterization of a New Mixture of Mono-Rhamnolipids Produced by Pseudomonas gessardii Isolated from Edmonson Point (Antarctica)

Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods

Contact Info

Product

Resources

About